Labcorp Launches RNA-Based At-Home Colorectal Cancer Test Nationwide
The test detect signs of colorectal cancer and precancerous growths using a home collection kit.
Category: Cancer
Cancer
Latest
Cancer
Latest
Blood Test Gains FDA Approval for First-Line HER2-Mutant Lung Cancer Treatment Selection
Guardant360 CDx can now identify patients eligible for zongertinib, the first targeted therapy approved as an initial treatment option for HER2-mutant advanced non-small cell lung cancer.
Cancer
Latest
Study Shows Blood Test Predicts Breast Cancer Recurrence Years Before Clinical Symptoms
Monitoring circulating tumor DNA dynamics outperformed standard markers for predicting survival and relapse in early-stage patients.
Personalis Data Highlights Early Cancer Recurrence Detection
Clinical results show high sensitivity for colorectal cancer relapse and ultra-low detection limits for lung cancer.
Read More
FDA Approves New Companion Diagnostics for Prostate Cancer Treatment
The tissue- and blood-based tests identify patients with specific gene mutations who may benefit from a combination therapy.
Read More
Large Study Shows Multi-Cancer Early Detection Test Increases Cancer Detection
Results from the PATHFINDER 2 trial show the Galleri test identifies 6.5 times more cancers when used with standard screenings.
Read More
DELFI Diagnostics Receives New York State Approval for Lung Cancer Blood Test
The authorization from the New York State Department of Health makes the screening test available in all 50 states.
Read More
Labcorp Collaborates on Trial to Expand Colorectal Cancer Genetic Testing
The multicenter study will evaluate proactive outreach to at-risk relatives and the impact of multigene panel testing on patient care.
Read More
New Biomarker May Improve Diagnosis of Rare Brain and Eye Cancers
The study identifies HAVCR1 as a tool for earlier detection and treatment monitoring for primary central nervous system lymphoma.
Read More
Roche Launches Algorithm Suite for Chronic Liver Disease Management
The panel integrates biomarker testing and digital tools to support fibrosis risk assessment and liver cancer surveillance.
Read More
ClearNote Health Raises $52 Million for Early Cancer Detection Tests
The funding will support commercial expansion of the company’s blood-based diagnostic tests and the appointment of a new president and chief operating officer.
Read More
ACS Updates Colorectal Cancer Screening Guidelines to Include Blood-Based and Stool Tests
The new recommendations add blood-based testing and multi-target stool testing as options for average-risk adults starting at age 45.
Read More
Roche to Acquire PathAI to Expand Digital Pathology and AI Diagnostics
The $750 million deal aims to integrate AI-powered technology and image management systems into pathology laboratory workflows.
Read More
ctDNA Blood Test May Help Guide Treatment Selection for Spreading Cancer
Research presented at ESTRO 2026 suggests circulating tumor DNA can identify which patients will benefit from combined radiation and drug therapy.
Read More
FDA Approves Companion Diagnostic to Identify NSCLC Patients Eligible for Tepmetko
The tissue-based test identifies patients with MET exon 14 skipping alterations eligible for treatment with tepotinib.
Read More
Tempus Launches AI-Powered Prostate Cancer Test for Metastatic Patients
Tempus has launched the ArteraAI Prostate Test, a CLIA-certified, CAP-accredited AI tool for metastatic hormone-sensitive prostate cancer, offering personalized risk estimates and designed to support treatment decisions, according to the company.
Read More
FDA Approves Guardant Health’s New Blood-Based Cancer Test for Advanced Tumors
The FDA has approved Guardant360 Liquid CDx, a blood-based test that integrates genomic and epigenomic profiling for advanced cancer, offering a broader genomic footprint and faster results.
Read More
TGen Launches 72-Hour Whole Genome Sequencing Test for Multiple Myeloma
TGen has launched JAYseq, a clinical whole genome sequencing test for multiple myeloma that delivers results in 72 hours, enabling rapid identification of genetic changes and immunotherapy targets, according to the institute.
Read More
- 1
- ...
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
- 175
- 176
- 177
- 178
- 179
- 180
- 181
- 182
- 183
- 184
- 185
- 186
- 187
- 188
- 189
- 190
- 191
- 192
- 193
- 194
- 195
- 196
- 197
- 198
- ...
- 199